跳到正文
Federal Register FDA 药品制造公告·AI 评分43

FDA 发布 FY2025 CDER 药品质量办公室体验式学习现场访问计划(ELSVP)公告并征集参与提案

Office of Pharmaceutical Quality Experiential Learning Site Visit Program; Program Announcement

AI 导读

FDA 宣布启动 FY2025 CDER 药品质量办公室(OPQ)体验式学习现场访问计划(ELSVP),邀请有意参与的制药企业向 CDER OPQ 提交现场访问提案。自 2024 年 10 月 1 日起,FDA 开始受理参与该计划的请求,提案可通过电子邮箱 CDEROPQSiteVisits@fda.hhs.gov 或书面方式提交。

正文 · 原文

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is announcing the Fiscal Year 2025 CDER Office of Pharmaceutical Quality (OPQ) Experiential Learning Site Visit Program (ELSVP). The purpose of this document is to invite pharmaceutical companies interested in participating in this program to submit a site visit proposal to CDER's OPQ.

DATES:

Starting October 1, 2024, FDA will accept requests to participate in the ELSVP program.

ADDRESSES:

If your facility is interested in offering a site visit, submit either an electronic proposal to CDEROPQSiteVisits@fda.hhs.gov or a written proposal to Lyle Canida (see FOR FURTHER INFORMATION CONTACT ). See the “III. Site Selection” and “IV. Proposals for Participation” sections of this document for potential priorities onsite selection criteria and how to submit a proposal to participate in the program.

来源:Federal Register FDA 药品制造公告 · federalregister.gov